Plasma Cell Disorder
9
4
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Pre-malignant States to Hematologic Malignancies in Firefighters
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing
Evaluation of the Plasma Cell Disorders Panel on the BD FACSLyric™ Flow Cytometer
Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias